Mizuho Securities Reiterates Buy on Questcor Pharmaceuticals on Stock Price Weakness

In a report published Tuesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating and $93.00 price target on Questcor Pharmaceuticals (NASDAQ: QCOR).

In the report, Mizuho Securities USA noted, “In the wake of today's stock price weakness on short report that FTC will challenge Synacthen deal, we ascertained that QCOR hasn't received a formal FTC inquiry, and anything informal might just be in response to updated HSR guidelines. Even if FTC pursued a court challenge, could take 2+ years to decide, and most recent product case went in favor of acquirer even though products looked more similar than Acthar/Synacthen.”

Questcor Pharmaceuticals closed on Monday at $56.26.